Evaluation of adherence to international guidelines for treating patients with type 2 diabetes mellitus in Kuwait
- 465 Downloads
Background Clinical guidelines derived from scientific evidence provide the basis of consistent standardized prescribing. Despite an alarming increase of diabetes in Kuwait, no studies related to the quality of prescribing in diabetes were found. Before pharmaceutical care can be implemented to improve the quality of care of patients with diabetes, it is important to determine whether prescribers are compliant with comprehensive international guidelines for cardioprevention and glycaemic control. Objective To evaluate the adherence to clinical guidelines for treating patients with type 2 diabetes mellitus in primary care centres and secondary care centres (hospitals) using a developed and validated medication assessment tool with reference to international guidelines. Setting Outpatient diabetes clinics in 8 primary care centres and 4 secondary care centres across four healthcare regions in Kuwait. Method A quantitative, cross-sectional study involving a sample of 652 Kuwaiti patients with type 2 diabetes, who were selected using systematic sampling from the study settings. Data were collected retrospectively from the patients’ medical records using a validated 43-criterion medication assessment tool (MATKW) designed to assess cardioprevention and treatment in patients with type 2 diabetes. Descriptive and comparative analysis was conducted using SPSS version 17. Main Outcome Measure Frequency of prescribing adherence to agreed definitions of criteria derived from international guidelines. Results Overall adherence to prescribing diabetes guidelines was 77.7 % (95 % CI 76.7–78.6 %). Significantly higher prescribing adherence was found in the secondary care facilities, 82.4 % (95 % CI 81.2–83.6 %) compared to primary care 72.5 % (95 % CI 71.0–73.9 %) (p < 0.001). Nineteen criteria out of 43 achieved an adherence >80 % in secondary care compared to ten criteria in primary care. The documentation of patients’ records was found to be inconsistent at the study healthcare facilities. Nonoptimal achievement of target goals for HbA1c, blood pressure and BMI was prevalent among the study population. Conclusion: A tool such as MATKW highlights areas for review and possible improvement in prescribing adherence. Our findings reveal problem areas in prescribing practices and documentation of patients’ records. Cost-effective multifaceted interventions are needed to improve current prescribing practices and documentation.
KeywordsClinical guidelines Kuwait Pharmaceutical care Prescribing Type 2 diabetes
We are grateful to all the physicians and the staff at the healthcare facilities for their assistance during data collection. The authors wish to acknowledge the contribution of the late Professor Steve Hudson (deceased) in the early stages of this work. We would also like to acknowledge Professor Lukman Thalib for his statistical advice. The MATKW is available on request by email from the corresponding author (firstname.lastname@example.org).
Conflicts of interest
- 1.International Diabetes Federation: IDF Diabetes Atlas. http://www.idf.org/diabetesatlas/5e/the-global-burden Accessed 25 Jan 2012.
- 3.World Health Organization. Diabetes Fact sheet No 312. Department of chronic diseases and health promotion. http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed 25 Dec 2011).
- 5.Advisory Commission on Health Consumer Protection and Quality in the Health Care Industry. Quality First: Better Health Care for All Americans. Washington: U.S. Government Printing Office; 1998.Google Scholar
- 10.Lenth RV. Java applets for power and sample size [Computer software]; 2006–2009. http://www.stat.uiowa.edu/~rlenth/Power/. Accessed 17 Dec 2009.
- 11.Guidelines on diabetes, pre-diabetes and cardiovascular diseases: The Task Force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;9 (suppl C): C3–C74. doi: 10.1093/eurheartj/ehl261.
- 12.Scottish Intercollegiate Guidelines Network. Heart disease guidelines 93–97. http://www.sign.ac.uk/guidelines/fulltext/93-97/index.html. Accessed 10 Nov 2009.
- 13.National Institute for Health and Clinical Excellence. CG66 Type 2 diabetes: full guideline. http://www.nice.org.uk/guidance/index.jsp?action=download&o=40803. Accessed 2009 Nov 7.
- 14.Diab M, Towle I, Johnson BJ, Hudson S. The quality of medication use in obesity management and in primary prevention of cardiovascular disease (CVD). Pharm World Sci. 2010;32:241.Google Scholar
- 18.Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ. 1998;317:465–8.PubMedCrossRefGoogle Scholar
- 20.Whitley HP, Fermo JD, Ragucci K, Chumney EC. Assessment of patient knowledge of diabetic goals, self-reported medication adherence, and goal attainment. Pharm Pract. 2006;4:183–90.Google Scholar